Core Viewpoint - The company, Plant Doctor, has initiated its IPO plan with impressive figures of "4,500 stores and 14 million members," but it faces significant internal control issues, stagnant performance, and concerns over R&D investment [1][5][7]. Group 1: Internal Control Issues - Plant Doctor has received 16 administrative penalties during the reporting period for issues such as false advertising and inadequate supply chain supervision [4][5]. - The company has a history of compliance failures, with 32 subsidiaries lacking health permits as of May 31, 2025, raising concerns about governance [6][5]. - The company's reliance on a franchise model has led to systemic risks, as evidenced by penalties against both its subsidiaries and franchisees [5][6]. Group 2: Stagnant Performance and Channel Challenges - From 2022 to 2024, Plant Doctor's revenue showed minimal growth, with figures of 2.117 billion, 2.151 billion, and 2.156 billion respectively, reflecting growth rates of 1.6% and 0.22% [7][8]. - In contrast, comparable companies in the industry have shown significant revenue growth, highlighting Plant Doctor's underperformance [7][8]. - The number of distributors decreased from 3,999 in early 2022 to 3,830 by the end of 2024, indicating a decline in the distribution network [9][10]. Group 3: R&D Investment Concerns - Despite claims of prioritizing R&D, the company reduced its R&D personnel by over 20% in two years, while total staff increased [12][13]. - The company spends significantly more on marketing (7.43 billion) compared to R&D, which raises concerns about its commitment to innovation [14][15]. - Core technologies are increasingly outsourced rather than developed in-house, leading to skepticism about the company's long-term technological capabilities [14][15].
王俊凯也带不动?植物医生IPO大喊重研发却悄悄缩减超20%研发人员
凤凰网财经·2025-07-15 07:17